capecitalox 500 mg
mylan ireland limited, Írsko - kapecitabín - 44 - cytostatica
erlotinib mylan 150 mg
mylan ireland limited, Írsko - erlotinib - 44 - cytostatica
erlotinib mylan 100 mg
mylan ireland limited, Írsko - erlotinib - 44 - cytostatica
imatinib mylan 400 mg
mylan ireland limited, Írsko - imatinib - 44 - cytostatica
imatinib mylan 100 mg
mylan ireland limited, Írsko - imatinib - 44 - cytostatica
sorafenib mylan 200 mg filmom obalené tablety
mylan ireland limited, Írsko - sorafenib - 44 - cytostatica
abiraterone mylan
mylan ireland limited - abiraterón acetátu - prostatické nádory - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
mifomet 50 mg/1000 mg
bausch health ireland limited, Írsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
mifomet 50 mg/850 mg
bausch health ireland limited, Írsko - metformín a sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)
mifoglame 100 mg
bausch health ireland limited, Írsko - sitagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)